Impact of 5-HT3 receptor antagonists on peripheral and central diseases

In this article we discuss the novel pharmacological aspects of 5-HT3 receptor antagonists. Commonly used to counteract chemotherapy-induced emesis, these agents now appear to be reaching out for newer indications. Studies have reported neuroprotective and anti-inflammatory properties in vitro and in vivo. 5-HT3 receptor antagonists can modulate the immune-inflammatory axis through blockade of 5-HT3 receptors present on immune cells. We review evidence addressing the effects of these drugs on peripheral inflammatory diseases, including asthma, rheumatoid diseases, inflammatory bowel disease and sepsis in addition to diabetes and CNS disorders, including Alzheimer's disease (AD), seizure and stroke.